Grant ID RP140522
Awarded On August 20, 2014
Title Reversing Vaccination-Induced Impairment of Anti-CTLA-4- Based Cancer Therapy
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Willem Overwijk
Cancer Sites Melanoma
Contracted Amount $899,991
Lay Summary

Anti-CTLA-4 antibody (ipilimumab, Yervoy®) is an effective new therapy for patients with metastatic melanoma that strengthens the immune system’s attack on cancer cells. Experimental vaccines against melanoma, including gp100 vaccine, are designed to do the same. Thus it was a surprise when combination of anti-CTLA-4 with gp100 vaccine did not work better, and in fact slightly worse, than anti-CTLA-4 alone. It is important to understand why vaccination did not improve anti-CTLA-4 therapy, because it was expected to be a very effective ways to improve anti-CTLA-4 therapy for the benefit of more patients with melanoma and possible other cancers. Because of these perplexing results, it is now u...

Read More